NeoGenomics, Inc. (NASDAQ:NEO) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have been assigned a consensus recommendation of “Hold” from the sixteen research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $13.1111.

NEO has been the topic of a number of analyst reports. Morgan Stanley set a $8.00 price objective on NeoGenomics and gave the company an “equal weight” rating in a research report on Wednesday, July 30th. TD Cowen lifted their price target on shares of NeoGenomics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, September 12th. Needham & Company LLC increased their price objective on shares of NeoGenomics from $8.00 to $14.00 and gave the stock a “buy” rating in a research note on Friday, August 29th. Piper Sandler set a $11.00 target price on shares of NeoGenomics and gave the company an “overweight” rating in a research note on Monday, August 4th. Finally, BTIG Research reaffirmed a “neutral” rating on shares of NeoGenomics in a report on Wednesday, July 30th.

NeoGenomics Trading Down 1.2%

Shares of NeoGenomics stock opened at $10.28 on Friday. NeoGenomics has a 1-year low of $4.72 and a 1-year high of $19.11. The company’s fifty day simple moving average is $9.39 and its 200-day simple moving average is $7.90. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.91 and a quick ratio of 3.58. The stock has a market capitalization of $1.33 billion, a PE ratio of -11.68 and a beta of 1.67.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, October 28th. The medical research company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.01. NeoGenomics had a negative return on equity of 3.36% and a negative net margin of 16.00%.The company had revenue of $187.80 million for the quarter, compared to analysts’ expectations of $183.85 million. During the same period last year, the firm earned $0.05 EPS. NeoGenomics’s revenue for the quarter was up 12.0% compared to the same quarter last year. NeoGenomics has set its FY 2025 guidance at 0.080-0.120 EPS. As a group, equities analysts anticipate that NeoGenomics will post -0.2 earnings per share for the current year.

Institutional Trading of NeoGenomics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Aster Capital Management DIFC Ltd grew its holdings in NeoGenomics by 42.5% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 3,341 shares of the medical research company’s stock valued at $26,000 after buying an additional 997 shares in the last quarter. Brooklyn Investment Group purchased a new position in NeoGenomics during the first quarter valued at $35,000. Headlands Technologies LLC bought a new stake in NeoGenomics in the 2nd quarter valued at $32,000. CWM LLC increased its holdings in NeoGenomics by 42.6% in the 1st quarter. CWM LLC now owns 6,299 shares of the medical research company’s stock valued at $60,000 after acquiring an additional 1,883 shares during the last quarter. Finally, AlphaQuest LLC purchased a new stake in NeoGenomics in the 1st quarter worth $60,000. Institutional investors own 98.50% of the company’s stock.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.